Canadian drugmaker Valeant Pharmaceuticals International Inc reported a quarterly profit, compared with a year-ago loss, driven by higher demand in the United States.
Continue Reading Below
The company also said Chief Financial Officer Howard Schiller would step down.
Net income attributable to shareholders was $73.7 million, or 21 cents per share, in the first quarter ended March 31, compared with a loss of $22.6 million, or 7 cents per share, a year earlier.
Revenue rose about 16 percent to $2.19 billion. (Reporting by Rosmi Shaji in Bengaluru; Editing by Maju Samuel)